ATP-activated P2X7 receptor in the pathophysiology of mood disorders and as an emerging target for the development of novel antidepressant therapeutics.

Mood disorders are a group of psychiatric conditions that represent leading global disease burdens. Increasing evidence from clinical and preclinical studies supports that innate immune system dysfunction plays an important part in the pathophysiology of mood disorders. P2X7 receptor, belonging to the ligand-gated ion channel P2X subfamily of purinergic P2 receptors for extracellular ATP, is highly expressed in immune cells including microglia in the central nervous system (CNS) and has a vital role in mediating innate immune response. The P2X7 receptor is also important in neuron-glia signalling in the CNS. The gene encoding human P2X7 receptor is located in a locus of susceptibility to mood disorders. In this review, we will discuss the recent progress in understanding the role of the P2X7 receptor in the pathogenesis and development of mood disorders and in discovering CNS-penetrable P2X7 antagonists for potential uses in in vivo imaging to monitor brain inflammation and antidepressant therapeutics.

• Publication year

  2018

• Venue

  Neuroscience and Biobehavioral Reviews

• Publication date

  2018-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.neubiorev.2018.02.005PMID 29453990
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Dipolar Cycloaddition Reaction To Access 6-Methyl-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridines Enables the Discovery Synthesis and Preclinical Profiling of a P2X7 Antagonist Clinical Candidate.

  2018influential reference
• Stereodivergent Synthesis of 2,3-Disubstituted 1,4-Dicarbonyls

  2018influential reference
• Depressive disorders: Processes leading to neurogeneration and potential novel treatments.

  2018cited by this paper
• 4-Methyl-6,7-dihydro-4H-triazolo[4,5-c]pyridine-Based P2X7 Receptor Antagonists: Optimization of Pharmacokinetic Properties Leading to the Identification of a Clinical Candidate.

  2017influential reference
• P2X7 receptor antagonism: Implications in diabetic retinopathy

  2017cited by this paper
• Molecular Targets for PET Imaging of Activated Microglia: The Current Situation and Future Expectations

  2017cited by this paper
• Escape from adamantane: Scaffold optimization of novel P2X7 antagonists featuring complex polycycles.

  2017cited by this paper
• The P2X7 receptor links mechanical strain to cytokine IL‐6 up‐regulation and release in neurons and astrocytes

  2017cited by this paper
• NLRP3 inflammasome-driven pathways in depression: Clinical and preclinical findings.

  2017cited by this paper
• 394. Development and Preclinical Evaluation of [18F]JNJ-64413739 as a PET Radioligand for P2X7 Receptors

  2017influential reference
• Heterozygosity for the Mood Disorder-Associated Variant Gln460Arg Alters P2X7 Receptor Function and Sleep Quality

  2017cited by this paper
• Discovery and pharmacological evaluation of a novel series of adamantyl cyanoguanidines as P2X7 receptor antagonists.

  2017influential reference
• Neuronal P2X7 Receptor: Involvement in Neuronal Physiology and Pathology

  2017cited by this paper
• Neuronal P2X7 Receptors Revisited: Do They Really Exist?

  2017cited by this paper
• P2X7 receptor antagonists: a patent review (2010–2015)

  2017cited by this paper
• Ketamine Alleviates Depressive-Like Behaviors via Down-Regulating Inflammatory Cytokines Induced by Chronic Restraint Stress in Mice.

  2017cited by this paper
• P2X7 Receptors Drive Spine Synapse Plasticity in the Learned Helplessness Model of Depression

  2017influential reference
• The P2X7 Receptor in Infection and Inflammation

  2017cited by this paper
• Peripheral Alterations in Cytokine and Chemokine Levels After Antidepressant Drug Treatment for Major Depressive Disorder: Systematic Review and Meta-Analysis

  2017cited by this paper
• Translocator Protein-18 kDa (TSPO) Positron Emission Tomography (PET) Imaging and Its Clinical Impact in Neurodegenerative Diseases

  2017cited by this paper
• Activation of P2X7 receptor and NLRP3 inflammasome assembly in hippocampal glial cells mediates chronic stress-induced depressive-like behaviors

  2017influential reference
• The P2X7 Receptor-Interleukin-1 Liaison

  2017cited by this paper
• The P2X7 receptor forms a dye-permeable pore independent of its intracellular domain but dependent on membrane lipid composition

  2017cited by this paper
• Design, synthesis and evaluation in an LPS rodent model of neuroinflammation of a novel 18F-labelled PET tracer targeting P2X7

  2017influential reference
• Pharmacological Evaluation of Novel Bioisosteres of an Adamantanyl Benzamide P2X7 Receptor Antagonist.

  2017influential reference
• PET Study of Sphingosine-1-Phosphate Receptor 1 Expression in Response to Vascular Inflammation in a Rat Model of Carotid Injury

  2017cited by this paper
• Localization of the gate and selectivity filter of the full-length P2X7 receptor

  2017cited by this paper
• Mechanism of microglia neuroprotection: Involvement of P2X7, TNFα, and valproic acid

  2016cited by this paper
• Integrating neuroimmune systems in the neurobiology of depression

  2016cited by this paper
• Psychological Stress Activates the Inflammasome via Release of Adenosine Triphosphate and Stimulation of the Purinergic Type 2X7 Receptor.

  2016influential reference
• The microglial ATP‐gated ion channel P2X7 as a CNS drug target

  2016influential reference
• Transient P2X7 Receptor Antagonism Produces Lasting Reductions in Spontaneous Seizures and Gliosis in Experimental Temporal Lobe Epilepsy

  2016cited by this paper
• Purinergic neurone-glia signalling in cognitive-related pathologies.

  2016cited by this paper
• ATP-induced P2X Receptor-Dependent Large Pore Formation: How Much Do We Know?

  2016cited by this paper
• Purinergic receptors in psychiatric disorders.

  2016cited by this paper
• Measurement of cardiovascular function using a novel view-sharing PET reconstruction method and tracer kinetic analysis

  2016influential reference
• NLRP3 inflammasome activation mediates estrogen deficiency-induced depression- and anxiety-like behavior and hippocampal inflammation in mice.

  2016influential reference
• Medicinal chemistry of adenosine, P2Y and P2X receptors.

  2016cited by this paper
• Role of neuro-immunological factors in the pathophysiology of mood disorders

  2016cited by this paper
• Co-Expression of Wild-Type P2X7R with Gln460Arg Variant Alters Receptor Function

  2016cited by this paper
• Structure-based identification and characterisation of structurally novel human P2X7 receptor antagonists

  2016cited by this paper
• P2X7 as a new target for chrysophanol to treat lipopolysaccharide-induced depression in mice.

  2016cited by this paper
• Preclinical characterization of substituted 6,7-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-8(5H)-one P2X7 receptor antagonists.

  2016influential reference
• Substituted 5,6-(Dihydropyrido[3,4-d]pyrimidin-7(8H)-yl)-methanones as P2X7 Antagonists.

  2016cited by this paper
• The evolution of P2X7 antagonists with a focus on CNS indications.

  2016cited by this paper
• Preclinical Evaluation of a P2X7 Receptor–Selective Radiotracer: PET Studies in a Rat Model with Local Overexpression of the Human P2X7 Receptor and in Nonhuman Primates

  2016influential reference
• New therapeutic opportunities for 5-HT2C receptor ligands in neuropsychiatric disorders.

  2016cited by this paper
• Role of neuro-immunological factors in the pathophysiology of mood disorders

  2016cited by this paper
• Identification of (R)-(2-Chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyridin-2-yl)-4-methyl-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (JNJ 54166060), a Small Molecule Antagonist of the P2X7 receptor.

  2016influential reference
• Neuron-microglia interaction by purinergic signaling in neuropathic pain following neurodegeneration.

  2016cited by this paper
• Novel Phenyl-Substituted 5,6-Dihydro-[1,2,4]triazolo[4,3-a]pyrazine P2X7 Antagonists with Robust Target Engagement in Rat Brain.

  2016influential reference
• New therapeutic opportunities for 5-HT2C receptor ligands in neuropsychiatric disorders.

  2016cited by this paper
• A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression

  2016cited by this paper
• X-ray structures define human P2X3 receptor gating cycle and antagonist action

  2016cited by this paper
• Author response: Structural basis for subtype-specific inhibition of the P2X7 receptor

  2016cited by this paper
• Structural basis for subtype-specific inhibition of the P2X7 receptor

  2016cited by this paper
• Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder

  2015cited by this paper
• A novel radioligand for the ATP-gated ion channel P2X7: [3H] JNJ-54232334.

  2015influential reference
• NLRP3 Inflammasome Mediates Chronic Mild Stress-Induced Depression in Mice via Neuroinflammation

  2015cited by this paper
• Purinergic system dysfunction in mood disorders: a key target for developing improved therapeutics.

  2015cited by this paper
• A rare P2X7 variant Arg307Gln with absent pore formation function protects against neuroinflammation in multiple sclerosis.

  2015cited by this paper
• Safety and Efficacy of an Oral Inhibitor of the Purinergic Receptor P2X7 in Adult Patients with Moderately to Severely Active Crohn's Disease: A Randomized Placebo-controlled, Double-blind, Phase IIa Study

  2015cited by this paper
• NLRP3 Inflammasome Activation by Viroporins of Animal Viruses

  2015cited by this paper
• Involvement of the P2X7 purinergic receptor in inflammation: an update of antagonists series since 2009 and their promising therapeutic potential.

  2015cited by this paper
• Synthesis of [11C]GSK1482160 as a new PET agent for targeting P2X7 receptor

  2015cited by this paper
• Docking of competitive inhibitors to the P2X7 receptor family reveals key differences responsible for changes in response between rat and human

  2015cited by this paper
• Novel methyl substituted 1-(5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanones are P2X7 antagonists.

  2015influential reference
• Quantitative structure–activity relationship study of P2X7 receptor inhibitors using combination of principal component analysis and artificial intelligence methods

  2015cited by this paper
• Medicinal chemistry of P2X receptors: agonists and orthosteric antagonists.

  2015cited by this paper
• Synthesis, SAR, and Pharmacological Characterization of Brain Penetrant P2X7 Receptor Antagonists.

  2015influential reference
• Synthesis of [(11)C]GSK1482160 as a new PET agent for targeting P2X(7) receptor.

  2015influential reference
• Nucleotide signalling during inflammation

  2014cited by this paper
• Role of P2X7 Receptor in an Animal Model of Mania Induced by D-Amphetamine

  2014influential reference
• Iptakalim confers an antidepressant effect in a chronic mild stress model of depression through regulating neuro-inflammation and neurogenesis.

  2014cited by this paper
• Nucleoside reverse transcriptase inhibitors possess intrinsic anti-inflammatory activity

  2014cited by this paper
• Neuroinflammation and Comorbidity of Pain and Depression

  2014cited by this paper
• Lack of Association of P2RX7 Gene rs2230912 Polymorphism with Mood Disorders: A Meta-Analysis

  2014cited by this paper
• P2X7‐dependent, but differentially regulated release of IL‐6, CCL2, and TNF‐α in cultured mouse microglia

  2014cited by this paper
• Synthesis and initial preclinical evaluation of the P2X7 receptor antagonist [¹¹C]A-740003 as a novel tracer of neuroinflammation.

  2014influential reference
• Purinergic receptor P2X₇: a novel target for anti-inflammatory therapy.

  2014cited by this paper
• The first CNS-active carborane: A novel P2X7 receptor antagonist with antidepressant activity.

  2014cited by this paper
• Pharmacology of a Novel Central Nervous System–Penetrant P2X7 Antagonist JNJ-42253432

  2014cited by this paper
• Inflammatory mediators of cognitive impairment in bipolar disorder.

  2014cited by this paper
• The P2X7 Receptor Channel: Recent Developments and the Use of P2X7 Antagonists in Models of Disease

  2014cited by this paper
• P2X7 antagonists as potential therapeutic agents for the treatment of CNS disorders.

  2014cited by this paper
• P2X7 receptor: an emerging target in central nervous system diseases.

  2014cited by this paper
• NLRP3 inflammasome is activated in mononuclear blood cells from patients with major depressive disorder.

  2014cited by this paper
• Microglial NLRP3 inflammasome activation mediates IL-1β-related inflammation in prefrontal cortex of depressive rats.

  2014cited by this paper
• The P2X7 receptor: shifting from a low- to a high-conductance channel - an enigmatic phenomenon?

  2014cited by this paper
• From stress to inflammation and major depressive disorder: a social signal transduction theory of depression.

  2014cited by this paper
• Non-Synonymous Single Nucleotide Polymorphisms in the P2X Receptor Genes: Association with Diseases, Impact on Receptor Functions and Potential Use as Diagnosis Biomarkers

  2014cited by this paper
• Deficient neuron-microglia signaling results in impaired functional brain connectivity and social behavior

  2014cited by this paper
• Astrocyte-derived ATP modulates depressive-like behaviors

  2013influential reference
• The Global Burden of Disease 2010 Study: what does it tell us about mental disorders in Latin America?

  2013cited by this paper
• P2X Receptor Intermediate Activation States Have Altered Nucleotide Selectivity

  2013cited by this paper
• Synthesis and Pharmacological Characterization of Two Novel, Brain Penetrating P2X7 Antagonists.

  2013influential reference
• P2X Receptors as Drug Targets

  2013cited by this paper
• Associations between depression severity and purinergic receptor P2RX7 gene polymorphisms.

  2013cited by this paper
• Insights into the Molecular Mechanisms Underlying Mammalian P2X7 Receptor Functions and Contributions in Diseases, Revealed by Structural Modeling and Single Nucleotide Polymorphisms

  2013cited by this paper
• Pharmacokinetic and pharmacodynamic profiling of a P2X7 receptor allosteric modulator GSK1482160 in healthy human subjects.

  2013cited by this paper

• NLRP3 activation by lipopolysaccharide (LPS) mediates the pyroptosis of human spermatogonial stem cells via GBP4 regulation.

  2026cites this paper
• A Comprehensive Review on Major Depressive Disorder: Exploring Etiology, Pathogenesis and Clinical Approaches

  2025cites this paper
• Microglia‐Derived Interleukin‐6 Triggers Astrocyte Apoptosis in the Hippocampus and Mediates Depression‐Like Behavior

  2025cites this paper
• The P2X7 receptor in depression: Novel insights and therapeutic implications.

  2025cites this paper
• P2X7 receptor: a potential target for treating comorbid anxiety and depression

  2024cites this paper
• Embers of the Past: Early Childhood Traumas Interact with Variation in P2RX7 Gene Implicated in Neuroinflammation on Markers of Current Suicide Risk

  2024cites this paper
• Role of purinoreceptors in the release of extracellular vesicles and consequences on immune response and cancer progression

  2024cites this paper
• Variation along P2RX7 interacts with early traumas on severity of anxiety suggesting a role for neuroinflammation

  2023cites this paper
• Leveraging the ATP‐P2X7 receptor signalling axis to alleviate traumatic CNS damage and related complications

  2023cites this paper
• Purinergic signaling: A gatekeeper of blood-brain barrier permeation

  2023cites this paper
• P2X3-selective mechanism of Gefapixant, a drug candidate for the treatment of refractory chronic cough

  2022cites this paper
• The P2X7 receptor in mood disorders: Emerging target in immunopsychiatry, from bench to bedside.

  2022cites this paper
• Origin, distribution, and function of three frequent coding polymorphisms in the gene for the human P2X7 ion channel

  2022cites this paper
• Recent advances in the development of antidepressants targeting the purinergic P2X7 receptor.

  2022cites this paper
• The Purinergic System as a Target for the Development of Treatments for Bipolar Disorder

  2022cites this paper
• Structural basis for the functional properties of the P2X7 receptor for extracellular ATP

  2021cites this paper
• [A Review of the State of Purinergic Signaling and Psychological Stress].

  2021cites this paper
• P2X7 receptor: a critical regulator and potential target for breast cancer

  2021cites this paper
• P2X7 Receptor as a Potential Target for Major Depressive Disorder.

  2021cites this paper
• Regulation of the NLRP3 Inflammasome by Post-Translational Modifications and Small Molecules

  2021cites this paper
• Purinergic transmission in depressive disorders.

  2021cites this paper
• Inflammatory response in epilepsy is mediated by glial cell gap junction pathway

  2021cites this paper
• P2X7R antagonists in chronic stress-based depression models: a review

  2021cites this paper
• Minimally invasive quantification of cerebral P2X7R occupancy using dynamic [18F]JNJ-64413739 PET and MRA-driven image derived input function

  2021influential citation
• Tyrosine 288 in the extracellular domain of the human P2X7 receptor is critical for receptor function revealed by structural modeling and site‐directed mutagenesis

  2021cites this paper
• Mechanosensing by Piezo1 and its implications for physiology and various pathologies

  2021cites this paper
• Characterisation of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males in a randomised, double-blind, placebo-controlled, multiple ascending dose trial

  2020cites this paper
• Purinergic Signaling and Related Biomarkers in Depression

  2020cites this paper
• P2X7 receptor mediates NLRP3 inflammasome activation in depression and diabetes

  2020cites this paper
• Pathological ATPergic Signaling in Major Depression and Bipolar Disorder

  2020cites this paper
• Targeting the P2X7 receptor in microglial cells to prevent brain inflammation

  2020cites this paper
• The P2X7 receptor: a new therapeutic target in Alzheimer’s disease

  2019cites this paper
• Adenosine Triphosphate Release and P2 Receptor Signaling in Piezo1 Channel-Dependent Mechanoregulation

  2019cites this paper
• P2X7 Receptors Drive Poly(I:C) Induced Autism-like Behavior in Mice

  2019cites this paper
• Automated Planar Patch-Clamp Recording of P2X Receptors.

  2019cites this paper
• Heterologous Expression and Patch-Clamp Recording of P2X Receptors in HEK293 Cells.

  2019cites this paper
• Translational Model‐Informed Dose Selection for a Human Positron Emission Tomography Imaging Study of JNJ‐54175446, a P2X7 Receptor Antagonist

  2019cites this paper
• Emerging role of the P2X7-NLRP3-IL1β pathway in mood disorders.

  2018cites this paper
• THEORETICAL ANALYSIS OF THE RELATIONSHIP BETWEEN THE ELECTRONIC STRUCTURE AND ITS INHIBITORY ACTION IN THE P2X7R RECEPTOR OF A SERIES OF 2-HYDROXY-1,4-NAPHTHOQUINONES DERIVATIVES

  2018cites this paper
• A P2X7 receptor antagonist reverses behavioural alterations, microglial activation and neuroendocrine dysregulation in an unpredictable chronic mild stress (UCMS) model of depression in mice.

  2018cites this paper